Comentar - Enviar para um amigo

Comentar - Enviar para um amigo

Comentar - Enviar para um amigo

Comentar - Enviar para um amigo

Comentar - Enviar para um amigo

The PubMed abstract display was modified to display results using a ranking algorithm when users click the author search link.

A filters sidebar tutorial is now available on YouTube.

The Filter Sidebar has replaced the Limits page in PubMed.

Preview the new Filter Sidebar in PubMed, coming soon.

The PubMed Send to menu has been updated to include a "Citation manager" selection.

Comentar - Enviar para um amigo

Comentar - Enviar para um amigo

Comentar - Enviar para um amigo

Comentar - Enviar para um amigo

Comentar - Enviar para um amigo

A 65-year-old man was referred by his general practitioner for an ECG at our hospital after a single episode of syncope occurring at rest. He had felt light-headed immediately before collapsing but had had no other symptoms. The ECG showed sinus rhythm at 68 beats per min, with striking prolongation of the QT interval (corrected for heart rate) 503 ms and he was admitted for cardiac monitoring and investigation. He had not previously had any similar episodes, palpitations, or chest pain. There was no relevant medical, family, or drug history.

Thomas Wakley—founding editor of The Lancet, member of Parliament, coroner and, for 12 years, all three simultaneously—died 150 years ago. His fullest biography is more than a century old, but still provides a good account of the struggles and achievements of this extraordinary yet at times rather difficult and overstretched man. Nonetheless, there are gaps, and this anniversary provides a chance to fill in a few of them.

Tuberculosis is still one of the most important causes of death worldwide. The 2010 Lancet tuberculosis series provided a comprehensive overview of global control efforts and challenges. In this update we review recent progress. With improved control efforts, the world and most regions are on track to achieve the Millennium Development Goal of decreasing tuberculosis incidence by 2015, and the Stop TB Partnership target of halving 1990 mortality rates by 2015; the exception is Africa. Despite these advances, full scale-up of tuberculosis and HIV collaborative activities remains challenging and emerging drug-resistant tuberculosis is a major threat.

Tuberculosis is still one of the most important causes of death worldwide. The 2010 Lancet tuberculosis series provided a comprehensive overview of global control efforts and challenges. In this update we review recent progress. With improved control efforts, the world and most regions are on track to achieve the Millennium Development Goal of decreasing tuberculosis incidence by 2015, and the Stop TB Partnership target of halving 1990 mortality rates by 2015; the exception is Africa. Despite these advances, full scale-up of tuberculosis and HIV collaborative activities remains challenging and emerging drug-resistant tuberculosis is a major threat.

Dabrafenib is safe in patients with solid tumours, and an active inhibitor of Val600-mutant BRAF with responses noted in patients with melanoma, brain metastases, and other solid tumours.

New England Journal of Medicine, Volume 366, Issue 20, Page 1924-1934, May 2012.

New England Journal of Medicine, Volume 366, Issue 20, May 2012.

New England Journal of Medicine, Volume 366, Issue 20, Page 1914-1922, May 2012.

New England Journal of Medicine, Volume 366, Issue 20, Page 1905-1913, May 2012.

New England Journal of Medicine, Volume 366, Issue 20, Page 1849-1853, May 2012.